Skip to main content
Caplight Logo









Skin2Neuron

Skin2Neuron

Private
SydneyHealthcare & Life Scienceshttps://www.s2n.bio/

Last Round

Grant

Sep 22, 2025

Total Funding Raised

$2.9M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Skin2Neuron is a regenerative medicine company developing a first-in-class autologous neurorestorative cell therapy derived from human hair follicles to treat neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

cell therapyregenerative medicineautologous cell therapyneurodegenerative diseaseAlzheimer's diseaseneuron regenerationhair follicle stem cellsneuroprecursor cellsneuronal culturesdisease modelingdisease in a dishdrug discoverynon-genetic modificationpreclinical researchParkinson's diseasetoxicity testingCDMO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Skin2Neuron Comparables

Compare Skin2Neuron with similar companies based on industry and business-model similarity.

Skin2Neuron comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Regeneration Biomedical, Inc.
80%
Aspen Neuroscience
76%
UCB
72%

Skin2Neuron Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 22, 2025
VC RoundOct 1, 2024
GrantMay 1, 2024

Key People

Founding team and executive leadership

Michael Valenzuela

Founder and Chief Scientific Officer

Founding Team

Skin2Neuron Investors

Notable investors and investment history

Skin2Neuron investors
InvestorRounds
CUREatorGrant
ArtesianVC Round
SYNthesis BioVenturesVC Round
Karst Peak RxVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 22, 2025

    $1.55M grant round led by CUREator

  • Aug 25, 2025

    Grew 30% QoQ, from 10 to 13 employees.

Skin2Neuron Filings

Explore SEC and related filing metadata, where available.

Skin2Neuron filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Skin2Neuron's valuation, stock price, and market status.

Is Skin2Neuron a public or private company?

Skin2Neuron is a private company.

What is the current stock price of Skin2Neuron?

Skin2Neuron is a private company with no public stock price. No recent secondary market data is available.

How much is Skin2Neuron worth (valuation)?

Valuation information for Skin2Neuron is not publicly available.

Can I buy Skin2Neuron stock?

Skin2Neuron shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Skin2Neuron's last funding round?

Funding round information for Skin2Neuron is not publicly available.

Who are the main investors in Skin2Neuron?

Investor information for Skin2Neuron is not publicly disclosed.

Will Skin2Neuron IPO soon?

No public IPO plans have been announced for Skin2Neuron.

How can I track Skin2Neuron secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Skin2Neuron's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSydney
Employee Range10
Year Founded2019
Last FundingSep 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?